Johnson Matthey (JM; London, UK) says it has entered into a five-year supply agreement with Sarepta Therapeutics (Andover, Massachusetts), a biopharmaceutical company.
According to the terms of the agreement, JM will continue to provide regulatory starting materials to support Sarepta’s programs for phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO), used for the treatment of Duchenne muscular dystrophy, the company says.
JM’s innovator products and solutions business that provides custom development and manufacturing (CDMO) services will produce these synthetic regulatory starting materials at its facilities at West Deptford, New Jersey, and Devens, Massachusetts, using their commercial-scale production trains, the company says.
The new agreement strengthens the relationship between the two companies. “Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta’s mission of engineering precision medicine for rare, devastating diseases,” says Alex Zahiri, vice president/innovator products and solutions, CDMO business at JM.
By: Sotirios Frantzanas
Source: Chemical Week
VEOLIA has agreed a deal to buy its rival Suez, ending a fraught takeover battle that merges the world’s two largest water and wastewater companies.
Borealis Group AG has commenced a new project to secure an increased supply of chemically recycled feedstock for the production of more circular base chemicals and polyolefin-based products.
The call is part of a campaign by Ceres, a nonprofit organization transforming the economy, and the We Mean Business coalition – a global, nonprofit coalition that collaborates with progressive businesses, to bolster action on climate change towards a zero-carbon economy.
